Literature DB >> 21225693

B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study.

W H Abdulahad1, J M Meijer, F G M Kroese, P M Meiners, A Vissink, F K L Spijkervet, C G M Kallenberg, H Bootsma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21225693     DOI： 10.1002/art.30236

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  17 in total

1.  Rituximab-mediated Raf kinase inhibitor protein induction modulates NF-κB in Sjögren syndrome.

Authors:  Margherita Sisto; Sabrina Lisi; Massimo D'Amore; Dario D Lofrumento
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

2.  Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.

Authors:  César Díaz-Torné; M Angels Ortiz de Juana; Carme Geli; Elisabet Cantó; Ana Laiz; Héctor Corominas; Jordi Casademont; Josep M de Llobet; Cándido Juárez; César Díaz-López; Sílvia Vidal
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

3.  Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.

Authors:  E William St Clair; Marc C Levesque; Eline T Luning Prak; Frederick B Vivino; Chacko J Alappatt; Meagan E Spychala; Josiah Wedgwood; James McNamara; Kathy L Moser Sivils; Lytia Fisher; Philip Cohen
Journal:  Arthritis Rheum       Date:  2013-04

4.  B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.

Authors:  Manuela Colucci; Rita Carsetti; Simona Cascioli; Federica Casiraghi; Annalisa Perna; Lucilla Ravà; Barbara Ruggiero; Francesco Emma; Marina Vivarelli
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

5.  Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.

Authors:  A Alunno; F Carubbi; O Bistoni; S Caterbi; E Bartoloni; P Di Benedetto; P Cipriani; R Giacomelli; R Gerli
Journal:  Clin Exp Immunol       Date:  2016-03-03       Impact factor: 4.330

Review 6.  What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

Authors:  Cees G M Kallenberg; Arjan Vissink; Frans G M Kroese; Wayel H Abdulahad; Hendrika Bootsma
Journal:  Arthritis Res Ther       Date:  2011-02-28       Impact factor: 5.156

7.  Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.

Authors:  Nils Venhoff; Nora M Effelsberg; Ulrich Salzer; Klaus Warnatz; Hans Hartmut Peter; Dirk Lebrecht; Michael Schlesier; Reinhard E Voll; Jens Thiel
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

8.  Advances in human B cell phenotypic profiling.

Authors:  Denise A Kaminski; Chungwen Wei; Yu Qian; Alexander F Rosenberg; Ignacio Sanz
Journal:  Front Immunol       Date:  2012-10-10       Impact factor: 7.561

Review 9.  B-cell targeted therapeutics in clinical development.

Authors:  Stephan Blüml; Kathleen McKeever; Rachel Ettinger; Josef Smolen; Ronald Herbst
Journal:  Arthritis Res Ther       Date:  2013-04-04       Impact factor: 5.156

10.  Lipopolysaccharide Attenuates CD40 Ligand-Induced Regulatory B10 Cell Expansion and IL-10 Production in Mouse Splenocytes.

Authors:  Mei Lin; Jiang Lin; Yuhua Wang; Nathalie Bonheur; Toshihisa Kawai; Zuomin Wang; Xiaozhe Han
Journal:  Open J Immunol       Date:  2015-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.